Latest Pfizer Inc (PFE) Headlines 3 Reasons Pfi
Post# of 190
Posted On: 03/14/2014 7:18:08 AM
Latest Pfizer Inc (PFE) Headlines
3 Reasons Pfizer, Inc. Can Overcome Celebrex Patent Loss
George Budwell, The Motley Fool - Motley Fool - Thu Mar 13, 5:30PM CDT
Pfizer lost its court battle yesterday to extend the patent life of its blockbuster painkiller, Celebrex, through 2015. Reportedly, there are five companies clamoring to sell cheaper, generic versions of the drug, with Mylan and Teva...
Most active New York Stock Exchange-traded stocks
AP - Thu Mar 13, 5:05PM CDT
NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at the close of trading:
Final Glance: Pharmaceuticals companies
AP - Thu Mar 13, 5:05PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were down at the close of trading:
Stocks Down 1% In Late Afternoon As Volume Picks Up
at Investor's Business Daily - Thu Mar 13, 2:54PM CDT
Stocks were down 1% or more late Thursday afternoon as ongoing worries about China and Ukraine trumped better-than-expected U.S. economic data. The Nasdaq slumped 1.4%, the Dow Jones industrial average lost 1.2%, with 28 of 30 issues lower. The S&P...
Pfizer Tumbles Beside a Triple-Digit Plunge for the Dow
Dan Carroll, The Motley Fool - Motley Fool - Thu Mar 13, 1:37PM CDT
The markets have taken a beating today, with the Dow Jones Industrial Average leaving investors shaking their heads with a 193-point fall as of 2:30 p.m. EDT. A ll but two of its blue-chip member stocks are down for the day. Despite a positive...
With FDA Concerns Public, What's Next for These Cholesterol Drugs?
Todd Campbell, The Motley Fool - Motley Fool - Thu Mar 13, 1:00PM CDT
Investors in Regeneron Amgen , and Pfizer got bad news last week when the FDA reportedly contacted the companies to express concerns that their high profile PCSK9 targeting cholesterol drugs may cause adverse neurological events. The FDA...
Midday Glance: Pharmaceuticals companies
AP - Thu Mar 13, 12:59PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are down at 1 p.m.:
Unfavorable Ruling for Pfizer - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 13, 12:50PM CDT
The court found Pfizer's reissue patent for Celebrex to be invalid.
Early Glance: Pharmaceuticals companies
AP - Thu Mar 13, 9:16AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
Morning Movers in Biotech: Actavis plc, DepoMed, Inc. and Horizon Pharma, Inc.
George Budwell, The Motley Fool - Motley Fool - Thu Mar 13, 8:09AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a look at the top stories in biotech and health...
March 13 Premarket Briefing: 10 Things You Should Know
at The Street - Thu Mar 13, 6:51AM CDT
U.S. stock futures rise ahead of U.S. jobless claims and retail sales data; FTC opens probe into Herbalife; GM says problems with ignition switches surfaced as early as 2001; Aeropostale and Plug Power to report quarterly results; Shell to cut U.S....
Concise Analysis of the International Orphan Drugs Industry
M2 - Thu Mar 13, 6:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/kdwn77/orphan_drugs) has announced the addition of the "Concise Analysis of the International Orphan Drugs Industry " report to their offering. This report analyzes the worldwide markets for Orphan Drugs in US$ Million. The report provides separate comprehensive analytics for the US, Europe, Japan, and Rest of World. Annual estimates and forecasts are provided for the period 2010 through 2018. Also, a six-year historic analysis is provided for these markets. The report profiles 113 companies including many key and niche players such as: - AbbVie Inc. - Actelion Pharmaceuticals Ltd. - Amgen Inc. - AstraZeneca plc - Bayer HealthCare AG - Biogen Idec Inc. - Bristol-Myers Squibb Company - Boehringer Ingelheim GmbH - Celgene Corporation - CEL-SCI Corporation - Eli Lilly and Company - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline Plc - Johnson & Johnson - Merck & Co. Inc. - Merck Serono International S.A. - Novartis AG - Pfizer Inc. - Recordati S.p.A. - Orphan Europe - Sanofi SA - Genzyme Corporation. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. For information on site licence pricing please click on Enquire before buying. Key Topics Covered: I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Industry Overview 2. Growth Drivers And Inhibitors 3. Challenges To Orphan Drug Development 4. Current Market Trends 5. Breakthroughs In Orphan Disease Treatment - A Ray Of Hope 6. Regulatory Scenario 7. Product Overview 8. Recent Orphan Designations & Approvals 9. Recent Industry Activity 10. Focus On Select Players 11. Global Market Perspective III. Market 1. The United States 2. Japan 3. Europe 4. Rest Of World IV. Competitive Landscape Total Companies Profiled: 113 (including Divisions/Subsidiaries - 121) - The United States (61) - Canada (4) - Japan (9) - Europe (42) - France (8) - Germany (3) - The United Kingdom (4) - Italy (4) - Rest of Europe (23) - Asia-Pacific (Excluding Japan) (3) - Middle East (2) For more information visit http://www.researchandmarkets.com/research/kd...phan_drugs
Pharmacovigilance Market Research Report - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
M2 - Thu Mar 13, 4:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rs95v7/pharmacovigilance) has announced the addition of the "Pharmacovigilance Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering. A rising tide of regulatory expectations, tougher inspection regime and instant need of patient reporting has provided the much needed impetus for the growth of the pharmacovigilance market. An upsurge in number of acute and chronic diseases has consequently led to a rise in number of drug consumption, which has also elicited a growth in the number of adverse drug events and drug toxicity cases. Moreover, several high-profile safety issues, regulatory warnings, large volume of events to be reviewed along with negative media coverage have compelled the pharmaceutical players to take support of various outsourcing services. There are two major outsourcing services opted by these pharmaceutical players i.e. traditional CROs and BPOs. These outsourcing services not only provide cost savings but also helps in bringing process efficiency. Pharmaceutical companies are now forming long term partnership with the CROs and BPOs to share the costs involved in PV process right from drug discovery to post marketing approvals. In addition, PV requires skilled resources with excellent language skills and strong knowledge pertaining to case reporting. The research report on pharmacovigilance provides detailed analysis of the global market and helps in understanding the driving forces responsible for the growth of this market. The report discusses the market of pharmacovigilance market on the bases of clinical trials phases i.e. Phase I to III and post marketing surveillance (PMS). We have also mapped the trend for preference of the pharmaceutical players for in-house and outsourcing in our chapter by type of service. The global pharmacovigilance market has been segmented based on all the above mentioned parameters and market size estimates and forecasts for the period of 2011 to 2019 have been provided for each of the segments, in term of USD million, considering 2012 as the base year for calculations and 2011 representing as the historical year. The CAGR (%) of each market segment for the forecast period 2013 to 2019 has also been provided along with market size estimations. The report exclusively studies the aforementioned segments with respect to geography. Under geographic section we have covered four regions, namely, North America, Europe, Asia-Pacific and Rest of the World (ROW). The market overview section gives a detailed qualitative analysis of the factors responsible for driving and restraining the growth of the global pharmacovigilance market. The section also covers opportunities and market attractiveness analysis of the geographical regions. The report concludes with the competitive landscape and company profiles of major market players. These market players have been profiled on the basis of various attributes such as company overview, financial overview, business strategies, product portfolio and recent developments. Key Topics Covered: Introduction Executive Summary Global Pharmacovigilance Market Dynamics Global Pharmacovigilance Market, by Clinical Trial Phases Global Pharmacovigilance Market, By Type of Methods Global Pharmacovigilance Market, by Type of Service Providers Global Pharmacovigilance Market, by Geography Global Pharmacovigilance Market Share Analysis Recommendations Company Profiles List of Figures List of Tables Companies Mentioned - Accenture, Plc - Bristol-Myers Squibb - Clinquest Group B.V. - Cognizant Technology Solutions - Covance, Inc. - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline (GSK) - iGATE Corporation - iMEDGlobal Corporation - inVentiv Health Inc. - ICON, Plc - Infosys - Johnson and Johnson - Novartis International AG - OptumInsight, Inc. - PRA International, Inc. - Parexel International Corporation - Pfizer, Inc. - Pharmaceutical Product Development, Inc. (PPD, Inc.) - Quantum Solutions India - Quintiles Transnational Corporation - Sanofi Aventis - Synowledge LLC - United BioSource Corporation - Wipro Limited For more information visit http://www.researchandmarkets.com/research/rs...ovigilance About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
'Fast Money' Recap: From Stocks to Bonds?
at The Street - Thu Mar 13, 4:00AM CDT
The trading panel discussed the S&P 500, copper and emerging markets.
Pfizer's
at Investor's Business Daily - Wed Mar 12, 5:49PM CDT
Pfizer's (PFE) patent on its best-selling anti-inflammatory drug Celebrex had been invalidated by a district court. The pharmaceutical giant had sued 5 makers of generic drugs that were trying to bring their off-brand drugs onto the market before the...
Study: Pfizer vaccine cuts pneumonia in elderly
By LINDA A. JOHNSON - AP - Wed Mar 12, 5:19PM CDT
TRENTON, N.J. (AP) — Pfizer Inc. said Wednesday that its blockbuster vaccine against pneumonia, blood and other infections met its goal of preventing illness in vulnerable elderly patients in a huge study required by U.S. regulators.
Business Highlights
By The Associated Press - AP - Wed Mar 12, 5:16PM CDT
___
3 Reasons Pfizer, Inc. Can Overcome Celebrex Patent Loss
George Budwell, The Motley Fool - Motley Fool - Thu Mar 13, 5:30PM CDT
Pfizer lost its court battle yesterday to extend the patent life of its blockbuster painkiller, Celebrex, through 2015. Reportedly, there are five companies clamoring to sell cheaper, generic versions of the drug, with Mylan and Teva...
Most active New York Stock Exchange-traded stocks
AP - Thu Mar 13, 5:05PM CDT
NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at the close of trading:
Final Glance: Pharmaceuticals companies
AP - Thu Mar 13, 5:05PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were down at the close of trading:
Stocks Down 1% In Late Afternoon As Volume Picks Up
at Investor's Business Daily - Thu Mar 13, 2:54PM CDT
Stocks were down 1% or more late Thursday afternoon as ongoing worries about China and Ukraine trumped better-than-expected U.S. economic data. The Nasdaq slumped 1.4%, the Dow Jones industrial average lost 1.2%, with 28 of 30 issues lower. The S&P...
Pfizer Tumbles Beside a Triple-Digit Plunge for the Dow
Dan Carroll, The Motley Fool - Motley Fool - Thu Mar 13, 1:37PM CDT
The markets have taken a beating today, with the Dow Jones Industrial Average leaving investors shaking their heads with a 193-point fall as of 2:30 p.m. EDT. A ll but two of its blue-chip member stocks are down for the day. Despite a positive...
With FDA Concerns Public, What's Next for These Cholesterol Drugs?
Todd Campbell, The Motley Fool - Motley Fool - Thu Mar 13, 1:00PM CDT
Investors in Regeneron Amgen , and Pfizer got bad news last week when the FDA reportedly contacted the companies to express concerns that their high profile PCSK9 targeting cholesterol drugs may cause adverse neurological events. The FDA...
Midday Glance: Pharmaceuticals companies
AP - Thu Mar 13, 12:59PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are down at 1 p.m.:
Unfavorable Ruling for Pfizer - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 13, 12:50PM CDT
The court found Pfizer's reissue patent for Celebrex to be invalid.
Early Glance: Pharmaceuticals companies
AP - Thu Mar 13, 9:16AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
Morning Movers in Biotech: Actavis plc, DepoMed, Inc. and Horizon Pharma, Inc.
George Budwell, The Motley Fool - Motley Fool - Thu Mar 13, 8:09AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a look at the top stories in biotech and health...
March 13 Premarket Briefing: 10 Things You Should Know
at The Street - Thu Mar 13, 6:51AM CDT
U.S. stock futures rise ahead of U.S. jobless claims and retail sales data; FTC opens probe into Herbalife; GM says problems with ignition switches surfaced as early as 2001; Aeropostale and Plug Power to report quarterly results; Shell to cut U.S....
Concise Analysis of the International Orphan Drugs Industry
M2 - Thu Mar 13, 6:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/kdwn77/orphan_drugs) has announced the addition of the "Concise Analysis of the International Orphan Drugs Industry " report to their offering. This report analyzes the worldwide markets for Orphan Drugs in US$ Million. The report provides separate comprehensive analytics for the US, Europe, Japan, and Rest of World. Annual estimates and forecasts are provided for the period 2010 through 2018. Also, a six-year historic analysis is provided for these markets. The report profiles 113 companies including many key and niche players such as: - AbbVie Inc. - Actelion Pharmaceuticals Ltd. - Amgen Inc. - AstraZeneca plc - Bayer HealthCare AG - Biogen Idec Inc. - Bristol-Myers Squibb Company - Boehringer Ingelheim GmbH - Celgene Corporation - CEL-SCI Corporation - Eli Lilly and Company - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline Plc - Johnson & Johnson - Merck & Co. Inc. - Merck Serono International S.A. - Novartis AG - Pfizer Inc. - Recordati S.p.A. - Orphan Europe - Sanofi SA - Genzyme Corporation. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. For information on site licence pricing please click on Enquire before buying. Key Topics Covered: I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Industry Overview 2. Growth Drivers And Inhibitors 3. Challenges To Orphan Drug Development 4. Current Market Trends 5. Breakthroughs In Orphan Disease Treatment - A Ray Of Hope 6. Regulatory Scenario 7. Product Overview 8. Recent Orphan Designations & Approvals 9. Recent Industry Activity 10. Focus On Select Players 11. Global Market Perspective III. Market 1. The United States 2. Japan 3. Europe 4. Rest Of World IV. Competitive Landscape Total Companies Profiled: 113 (including Divisions/Subsidiaries - 121) - The United States (61) - Canada (4) - Japan (9) - Europe (42) - France (8) - Germany (3) - The United Kingdom (4) - Italy (4) - Rest of Europe (23) - Asia-Pacific (Excluding Japan) (3) - Middle East (2) For more information visit http://www.researchandmarkets.com/research/kd...phan_drugs
Pharmacovigilance Market Research Report - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
M2 - Thu Mar 13, 4:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rs95v7/pharmacovigilance) has announced the addition of the "Pharmacovigilance Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering. A rising tide of regulatory expectations, tougher inspection regime and instant need of patient reporting has provided the much needed impetus for the growth of the pharmacovigilance market. An upsurge in number of acute and chronic diseases has consequently led to a rise in number of drug consumption, which has also elicited a growth in the number of adverse drug events and drug toxicity cases. Moreover, several high-profile safety issues, regulatory warnings, large volume of events to be reviewed along with negative media coverage have compelled the pharmaceutical players to take support of various outsourcing services. There are two major outsourcing services opted by these pharmaceutical players i.e. traditional CROs and BPOs. These outsourcing services not only provide cost savings but also helps in bringing process efficiency. Pharmaceutical companies are now forming long term partnership with the CROs and BPOs to share the costs involved in PV process right from drug discovery to post marketing approvals. In addition, PV requires skilled resources with excellent language skills and strong knowledge pertaining to case reporting. The research report on pharmacovigilance provides detailed analysis of the global market and helps in understanding the driving forces responsible for the growth of this market. The report discusses the market of pharmacovigilance market on the bases of clinical trials phases i.e. Phase I to III and post marketing surveillance (PMS). We have also mapped the trend for preference of the pharmaceutical players for in-house and outsourcing in our chapter by type of service. The global pharmacovigilance market has been segmented based on all the above mentioned parameters and market size estimates and forecasts for the period of 2011 to 2019 have been provided for each of the segments, in term of USD million, considering 2012 as the base year for calculations and 2011 representing as the historical year. The CAGR (%) of each market segment for the forecast period 2013 to 2019 has also been provided along with market size estimations. The report exclusively studies the aforementioned segments with respect to geography. Under geographic section we have covered four regions, namely, North America, Europe, Asia-Pacific and Rest of the World (ROW). The market overview section gives a detailed qualitative analysis of the factors responsible for driving and restraining the growth of the global pharmacovigilance market. The section also covers opportunities and market attractiveness analysis of the geographical regions. The report concludes with the competitive landscape and company profiles of major market players. These market players have been profiled on the basis of various attributes such as company overview, financial overview, business strategies, product portfolio and recent developments. Key Topics Covered: Introduction Executive Summary Global Pharmacovigilance Market Dynamics Global Pharmacovigilance Market, by Clinical Trial Phases Global Pharmacovigilance Market, By Type of Methods Global Pharmacovigilance Market, by Type of Service Providers Global Pharmacovigilance Market, by Geography Global Pharmacovigilance Market Share Analysis Recommendations Company Profiles List of Figures List of Tables Companies Mentioned - Accenture, Plc - Bristol-Myers Squibb - Clinquest Group B.V. - Cognizant Technology Solutions - Covance, Inc. - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline (GSK) - iGATE Corporation - iMEDGlobal Corporation - inVentiv Health Inc. - ICON, Plc - Infosys - Johnson and Johnson - Novartis International AG - OptumInsight, Inc. - PRA International, Inc. - Parexel International Corporation - Pfizer, Inc. - Pharmaceutical Product Development, Inc. (PPD, Inc.) - Quantum Solutions India - Quintiles Transnational Corporation - Sanofi Aventis - Synowledge LLC - United BioSource Corporation - Wipro Limited For more information visit http://www.researchandmarkets.com/research/rs...ovigilance About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
'Fast Money' Recap: From Stocks to Bonds?
at The Street - Thu Mar 13, 4:00AM CDT
The trading panel discussed the S&P 500, copper and emerging markets.
Pfizer's
at Investor's Business Daily - Wed Mar 12, 5:49PM CDT
Pfizer's (PFE) patent on its best-selling anti-inflammatory drug Celebrex had been invalidated by a district court. The pharmaceutical giant had sued 5 makers of generic drugs that were trying to bring their off-brand drugs onto the market before the...
Study: Pfizer vaccine cuts pneumonia in elderly
By LINDA A. JOHNSON - AP - Wed Mar 12, 5:19PM CDT
TRENTON, N.J. (AP) — Pfizer Inc. said Wednesday that its blockbuster vaccine against pneumonia, blood and other infections met its goal of preventing illness in vulnerable elderly patients in a huge study required by U.S. regulators.
Business Highlights
By The Associated Press - AP - Wed Mar 12, 5:16PM CDT
___
(0)
(0)Pfizer Inc. (PFE) Stock Research Links
Scroll down for more posts ▼